NLRP3 and neoplasm: Characterization of several preclinical tumor models and clinical specimens found that while CD8+ T cells were activated by PD-1 blocking, these CD8+ T cells induced PD-L1-NLRP3 inflammatory signal cascades in tumor cells, resulting in recruitment of granulocytic MDSCs (PMN-MDSCs) into tumor tissue, thus inhibiting anti-tumor immune response.